Related Experiment Videos
Locally advanced breast cancer
1Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA.
Hematology/Oncology Clinics of North America
|June 11, 1999
Summary
Management of locally advanced breast cancer (LABC) has evolved with chemotherapy, endocrine therapy, surgery, and radiation therapy. This review covers taxanes, novel endocrine agents, high-dose chemotherapy, and tumor markers for LABC treatment.
Area of Science:
- Oncology
- Medical treatment of cancer
Background:
- Multidisciplinary management of locally advanced breast cancer (LABC) has significantly evolved over 30 years.
- Chemotherapy (CT), endocrine therapy, surgery, and radiation therapy (XRT) have altered the disease's natural history.
Purpose of the Study:
- To review advancements in the multidisciplinary management of LABC.
- To discuss the role of novel therapeutic agents and prognostic markers in LABC.
Main Methods:
- Review of current literature and treatment modalities for LABC.
- Discussion of chemotherapy regimens, endocrine therapies, and surgical options.
- Analysis of prognostic and predictive tumor markers in LABC management.
Main Results:
- Taxanes, novel endocrine therapies, and high-dose CT programs are key components in LABC management.
- Breast-conserving surgery is increasingly indicated for LABC.
- Prognostic and predictive tumor markers play a crucial role in tailoring LABC treatment.
Conclusions:
- The integrated approach to LABC management has improved patient outcomes.
- Personalized treatment strategies based on tumor markers are essential for effective LABC care.